Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals' stock price has declined by approximately 49.34% in the past six months. Key events include the FDA accelerated approval and launch of OJEMDA, the sale of a Priority Review Voucher for $108 million, a licensing agreement with Ipsen, and a private placement of securities for approximately $175.0 million. The company reported Q4 2024 financial results in February 2025, Q1 2025 financial results in May 2025, and Q2 2025 results with EPS of -$0.29, beating estimates. Analysts have provided varying outlooks on the stock.

There is some indication of demand seasonality for Day One Biopharmaceuticals' products, particularly OJEMDA. April has shown strong new patient starts, suggesting a positive rebound after a seasonal dip in January. Q4 can also experience some seasonality, which may reduce the number of patients initiating therapy. Q1 typically sees a higher gross-to-net ratio due to a January price increase and modest increases in co-pay assistance for patients. The company anticipates a consistent, steady ramp for new patient starts.

Day One Biopharmaceuticals is dedicated to developing and commercializing targeted therapies for patients with genetically defined cancers. Its lead product candidate, tovorafenib (OJEMDA), received accelerated FDA approval in April 2024 for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG) in patients aged 6 months and older. Tovorafenib is being evaluated in Phase 2 and Phase 3 clinical trials. The company's pipeline also includes pimasertib, DAY301, and a VRK1 Inhibitor.

Day One Biopharmaceuticals is headquartered in Brisbane, California, with a presence in South San Francisco. It has an exclusive ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib, indicating an international reach.

Day One Biopharmaceuticals' brand reputation is positively influenced by advancements in pediatric cancer treatment and favorable analyst sentiment. The ongoing Phase 2 study for tovorafenib and the accelerated FDA approval and launch of OJEMDA contribute positively to its reputation. There have been no widely reported events that have negatively impacted Day One Biopharmaceuticals' brand reputation in the past year.

Day One Biopharmaceuticals is primarily owned by institutional shareholders (84.14%) and insiders (63.73%), with a smaller percentage held by retail investors. Major institutional owners include Fmr LLC, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, Vanguard Group Inc, Franklin Resources Inc, Deerfield Management Company, L.p. (series C), Pictet Asset Management Holding SA, Alyeska Investment Group, L.P., Vestal Point Capital, LP and State Street Corp. The largest individual shareholder is Ai Day1 LLC, owning 12.62% of the company.